Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02812342 · ClinicalTrials.gov registry record · Phase 2
Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02812342 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 10 participants.
The verdict
NCT02812342, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate the use of topical tofacitinib to promote hair regrowth in patients with alopecia areata, alopecia totalis, and alopecia universalis.
Interventions
- DRUG Tofacitinib ointment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-09 |
| Est. Completion | 2018-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02812342
The ClinicalTrials.gov registry entry for NCT02812342 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tofacitinib ointment is the first listed.
NCT02812342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02812342 about?
NCT02812342 is a clinical study titled "Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants". The purpose of the study is to investigate the use of topical tofacitinib to promote hair regrowth in patients with alopecia areata, alopecia totalis, and alopecia universalis.
What is the current status of trial NCT02812342?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2016-09. Estimated completion is 2018-12.
What interventions are being tested in trial NCT02812342?
The interventions under investigation include: Tofacitinib ointment (DRUG).
Who is sponsoring clinical trial NCT02812342?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.